Apitegromab
Low EvidenceApitegromab (SRK-015) is an investigational, fully human IgG4 monoclonal antibody developed by Scholar Rock that inhibits myostatin - the muscle-produced growth factor that limits skeletal-muscle mass - through a novel, muscle-selective mechanism. Rather than neutralizing mature, active myostatin (the approach of earlier failed inhibitors), apitegromab binds only the inactive precursor forms of the protein - promyostatin and latent myostatin - stored locally in muscle, and blocks their proteolytic conversion into the active ligand. Because it spares the closely related growth factors activin A, BMP9/10, and TGF-beta1, it aims to avoid the off-target effects (such as bleeding and vascular changes) that sank broad ActRII-pathway drugs. Apitegromab is the first muscle-targeted therapy to succeed in a pivotal Phase 3 trial in spinal muscular atrophy (SMA): in the 156-patient SAPPHIRE study of nonambulatory Type 2/3 patients aged 2-12 already on an SMN-directed therapy (nusinersen or risdiplam), adding apitegromab (10 or 20 mg/kg IV every 4 weeks) improved motor function by a pooled 1.8 points on the Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo at 12 months (p=0.019). Scholar Rock's initial Biologics License Application received an FDA Complete Response Letter in September 2025 tied solely to a third-party (Catalent Indiana) fill-finish manufacturing inspection - not to the drug's efficacy or safety - and the company resubmitted the BLA on March 31, 2026, with a PDUFA target action date of September 30, 2026. In parallel, apitegromab produced positive Phase 2 obesity data (EMBRAZE): added to tirzepatide over 24 weeks it preserved about 55% more lean mass (roughly 1.9 kg / 4.2 lb) than tirzepatide alone, positioning myostatin inhibition as a potential lean-mass-sparing partner for GLP-1-based weight loss.
What It Is
Apitegromab (development code SRK-015) is an investigational biologic - a fully human IgG4 monoclonal antibody - from Scholar Rock that targets myostatin (also called GDF-8), the body's built-in brake on skeletal-muscle growth. Myostatin is made and stored in muscle as inactive precursors (promyostatin and latent myostatin) that are later cleaved into the active hormone; active myostatin then signals through the ActRII receptors to restrain muscle size. Earlier myostatin-pathway drugs tried to block the active ligand or its receptor broadly, which also hit related TGF-beta-family proteins (activin A, BMP9/10) and produced dose-limiting side effects and clinical failures. Apitegromab takes a more selective route: it binds the pro- and latent forms of myostatin inside muscle and prevents their activation, so it dials down myostatin signaling without disturbing the neighboring growth factors. This 'muscle-directed' selectivity is the molecule's core differentiator from broad inhibitors such as the ActRII-blocking antibody bimagrumab and the myostatin/activin decoy-receptor taldefgrobep alfa. Its lead indication is spinal muscular atrophy, a genetic motor-neuron disease in which the existing SMN-restoring drugs (nusinersen/Spinraza, risdiplam/Evrysdi, and the gene therapy onasemnogene abeparvovec/Zolgensma) preserve motor neurons but leave residual muscle weakness; apitegromab is designed to strengthen the muscle itself on top of that background therapy. After the positive Phase 2 TOPAZ study, the Phase 3 SAPPHIRE trial made apitegromab the first muscle-targeted candidate to hit its primary motor-function endpoint in SMA. A separate franchise is emerging in obesity: because GLP-1 and GLP-1/GIP weight-loss drugs strip away a substantial fraction of lean muscle along with fat, apitegromab is being studied to protect muscle during that weight loss, with positive Phase 2 EMBRAZE data alongside tirzepatide. Scholar Rock is also running the Phase 2 OPAL study in infants and toddlers under two with SMA, advancing apitegromab into facioscapulohumeral muscular dystrophy (FSHD), and developing a subcutaneous follow-on (SRK-439) for obesity.
Regulatory Status
Why Researchers Study It
Apitegromab is the first myostatin/muscle-directed therapy to succeed in a pivotal Phase 3 trial in a neuromuscular disease, validating the long-pursued idea that inhibiting myostatin can meaningfully improve muscle function in patients - here, on top of SMN-restoring SMA drugs that fix the nerve but not the muscle. Its precursor-selective mechanism is studied as a template for hitting myostatin hard while avoiding the off-target liabilities that doomed earlier inhibitors. The molecule has also become a focal point of the obesity field: as GLP-1-class drugs drive dramatic weight loss but sacrifice lean muscle, apitegromab's positive EMBRAZE data make it a leading test of whether myostatin inhibition can preserve muscle quality during pharmacologic weight loss, potentially as a combination partner for incretin therapies.
Proposed Mechanisms
- Precursor-selective myostatin inhibition: apitegromab binds the inactive precursor forms of myostatin - promyostatin and latent myostatin - stored in skeletal muscle, blocking their proteolytic activation into mature, signaling myostatin (GDF-8).
- Reduced ActRII signaling: by lowering the pool of active myostatin, it decreases activation of the activin type II receptors and downstream SMAD2/3 signaling that restrains muscle growth, favoring muscle hypertrophy and function.
- Growth-factor selectivity: it spares the closely related ligands activin A, BMP9/10, and TGF-beta1, an intended contrast to broad ActRII-pathway inhibitors and a strategy to avoid off-target bleeding and vascular effects.
- Complementary to SMN-directed therapy in SMA: acting on muscle rather than the motor neuron, it is designed to add motor-function benefit on top of nusinersen, risdiplam, or gene therapy that preserve or restore the neuron.
- Lean-mass preservation during weight loss: sustained muscle-directed myostatin inhibition is proposed to protect skeletal muscle while GLP-1/GIP agonists (e.g., tirzepatide) drive fat and overall weight loss.
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| RCT (human, Phase 3 - SAPPHIRE, 12 months) | 156 nonambulatory Type 2/3 SMA patients aged 2-12 on background SMN therapy (nusinersen or risdiplam); apitegromab 10 or 20 mg/kg IV every 4 weeks vs placebo (1:1:1) | Met primary endpoint: pooled mean HFMSE improvement of ~1.8 points vs placebo at 12 months (p=0.019); the 10 mg/kg arm showed a ~2.2-point difference (nominal p=0.0121). First muscle-targeted therapy to succeed in a pivotal SMA trial; generally well tolerated. | Source |
| RCT (human, Phase 2 - EMBRAZE, 24 weeks, obesity) | Adults with obesity receiving tirzepatide; apitegromab 10 mg/kg added vs tirzepatide alone | Statistically significant preservation of lean mass: apitegromab preserved ~54.9% more lean mass (about 1.9 kg / 4.2 lb) than tirzepatide alone over 24 weeks, supporting myostatin inhibition as a lean-mass-sparing partner for GLP-1/GIP weight loss. | Source |
| Human (Phase 2 - TOPAZ / open-label extensions and OPAL, ongoing) | Earlier Phase 2 TOPAZ study in Type 2/3 SMA (proof-of-concept for HFMSE gains) and the ongoing Phase 2 OPAL study in infants/toddlers under 2 with SMA on SMN-directed therapy or gene therapy | TOPAZ demonstrated motor-function improvements that supported SAPPHIRE; OPAL extends evaluation to the youngest SMA patients, with dosing underway. Long-term extension data continue to accrue. | Source |
Commonly Discussed Benefits
Researching Apitegromab? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Not approved by any regulator; the initial U.S. BLA received a Complete Response Letter in September 2025 (manufacturing/fill-finish inspection related), and approval now depends on the resubmitted BLA and a September 30, 2026 PDUFA decision.
- Efficacy is established in SMA when added to SMN-directed therapy in nonambulatory Type 2/3 patients; benefit in other SMA populations, in obesity, or in FSHD is not yet proven by pivotal data.
- Administered by intravenous infusion every 4 weeks (a subcutaneous follow-on, SRK-439, is separate and earlier-stage).
- Long-term effects of sustained myostatin inhibition are unknown; earlier myostatin-pathway drugs failed or showed off-target effects in other diseases.
- Obesity (EMBRAZE) data are Phase 2 and short-term; durability, functional/strength outcomes, and safety of long-term use with GLP-1 drugs remain to be established.
Comparisons
See how Apitegromab compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in SMA - Scholar Rock (2024) PubMed
- [2] FDA Issues Complete Response Letter for Apitegromab Solely Related to Observations at Catalent Indiana Fill-Finish Facility - Scholar Rock (Sept 2025) PubMed
- [3] Scholar Rock Resubmits BLA to FDA for Apitegromab for Children and Adults with SMA (March 31, 2026) PubMed
- [4] Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss - Scholar Rock PubMed
- [5] Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3 (TOPAZ) - Neurology PubMed
Keep researching in the app
- Log Apitegromab to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Bimagrumab
Medium EvidenceAn anti-activin type II receptor antibody that promotes fat loss while preserving lean muscle mass, studied in combination with GLP-1 agonists for obesity.
Taldefgrobep Alfa
Low EvidenceA novel myostatin-activin pathway inhibitor targeting fat reduction and lean mass gain, with Phase 2 results in obesity expected H2 2026.
Zilucoplan
High EvidenceA self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis.
Trevogrumab
Medium EvidenceTrevogrumab (REGN1033) is an investigational fully human anti-myostatin (anti-GDF8) monoclonal antibody from Regeneron being tested as a lean-mass-sparing add-on to semaglutide in the Phase 2 COURAGE obesity trial; adding it to semaglutide prevented roughly half of the ~33% of GLP-1-induced weight loss that normally comes from muscle, and the semaglutide + trevogrumab + garetosmab triplet reached 13.4% weight loss at 26 weeks with only ~7.4% of that loss from lean mass.
Garetosmab
Medium EvidenceGaretosmab (REGN2477) is Regeneron's investigational fully human anti-activin A monoclonal antibody. In the Phase 3 OPTIMA trial in adults with the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP), it cut new heterotopic bone lesions by ~90-94% and reduced new-lesion volume by >99% versus placebo; its BLA was accepted for FDA Priority Review with an August 2026 target action date. The same activin A blockade also makes garetosmab the muscle-preserving partner to trevogrumab and semaglutide in the Phase 2 COURAGE obesity program.
Sotatercept
High EvidenceSotatercept (Winrevair, sotatercept-csrk) is Merck's first-in-class activin signaling inhibitor - a recombinant ActRIIA-Fc fusion protein that acts as a ligand trap for activin A, activin B, GDF-8 (myostatin) and GDF-11. It is FDA-approved for adults with pulmonary arterial hypertension (PAH), where it improved 6-minute walk distance by 40.8 meters in the Phase 3 STELLAR trial and, in the Phase 3 ZENITH trial in high-risk patients, cut the composite risk of death, lung transplantation and PAH hospitalization by 76%. An expanded U.S. label reflecting ZENITH was approved on October 27, 2025.